ATTO stock trades at $19.86, down 9.32% from its IPO, with a $287.9 million market cap and no revenue expected for years.
Attovia Therapeutics (NASDAQ:ATTO) opened at $21.90 but now trades near $19.86, a 9.32% decline from its IPO price. The stock’s market capitalization stands at $287.9 million after eight trading sessions, reflecting investor caution over its long-term pipeline.
The clinical-stage biotech, backed by $256 million in funding, focuses on blocking IL-31, a cytokine linked to chronic itch. Its lead asset, ATTO-1310, remains in Phase 1 trials, with commercial revenue not expected before 2027. The company’s entire pipeline hinges on its Attobody platform, in-licensed from Alamar Biosciences.
Shares rose 3.6% on the session but remain below the IPO print, signaling mixed early sentiment. The stock’s performance contrasts with broader biotech trends, where pre-revenue firms often face volatility.